These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21308453)

  • 1. Update on strongyloidiasis in the immunocompromised host.
    Marcos LA; Terashima A; Canales M; Gotuzzo E
    Curr Infect Dis Rep; 2011 Feb; 13(1):35-46. PubMed ID: 21308453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late post-kidney transplant Strongyloides hyperinfection syndrome.
    Nishio Lucar A; Knicely DH; Sifri CD
    Transpl Infect Dis; 2018 Dec; 20(6):e12975. PubMed ID: 30107075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-Derived Strongyloidiasis Infection in Solid Organ Transplant Recipients: A Review and Pooled Analysis.
    Kim JH; Kim DS; Yoon YK; Sohn JW; Kim MJ
    Transplant Proc; 2016 Sep; 48(7):2442-2449. PubMed ID: 27742318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strongyloidiasis in transplant patients.
    Roxby AC; Gottlieb GS; Limaye AP
    Clin Infect Dis; 2009 Nov; 49(9):1411-23. PubMed ID: 19807271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of a Strongyloides screening strategy in solid organ transplant donors and recipients.
    Camargo JF; Simkins J; Anjan S; Guerra G; Vianna R; Salama S; Albright C; Shipman E; Montoya J; Morris MI; Abbo LM
    Clin Transplant; 2019 Apr; 33(4):e13497. PubMed ID: 30773692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal strongyloidiasis and hyperinfection syndrome.
    Vadlamudi RS; Chi DS; Krishnaswamy G
    Clin Mol Allergy; 2006 May; 4():8. PubMed ID: 16734908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplant-related strongyloidiasis in solid organ transplant recipients in Saudi Arabia and the Gulf Cooperation Council countries.
    Elzein F; Albahili H; Bahloul A; Alonazi T; Alghamdi A; Alsufyani E; Musa A; Alsaeed M
    Int J Infect Dis; 2020 Apr; 93():133-138. PubMed ID: 31982623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of subcutaneous ivermectin for the treatment of
    Zeitler K; Jariwala R; Restrepo-Jaramillo R; Kapadia S; Casanas B; Alrabaa S; Sriaroon C
    BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29866667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS.
    Torres JR; Isturiz R; Murillo J; Guzman M; Contreras R
    Clin Infect Dis; 1993 Nov; 17(5):900-2. PubMed ID: 8286637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Strongyloides Infection Postchemotherapy.
    Merman E; Siddha S; Keystone JS; Al Habeeb A; Ghazarian D; Cy A; Rosen CF
    J Cutan Med Surg; 2016 Jul; 20(4):337-9. PubMed ID: 26896181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report.
    Pacanowski J; Santos MD; Roux A; LE Maignan C; Guillot J; Lavarde V; Cornet M
    Am J Trop Med Hyg; 2005 Jul; 73(1):122-4. PubMed ID: 16014846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strongyloides hyperinfection in a patient with solid malignant tumor a case report.
    GeethaBanu S; Arthi K
    Indian J Public Health; 2020; 64(1):90-92. PubMed ID: 32189692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptococcus pyogenes bacteremia and toxic shock syndrome related to Strongyloides stercoralis hyperinfection: a case report.
    Cohen R; Finn T; Babushkin F; Shapiro M; Uda M; Grossman T
    J Med Case Rep; 2018 Nov; 12(1):346. PubMed ID: 30463627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous ivermectin for the treatment of the hyperinfection syndrome by Strongyloides stercoralis.
    Hennessey DC; Ballesteros ÓA; Merchán DJ; Guevara FO; Severiche DF
    Biomedica; 2020 Jun; 40(2):228-232. PubMed ID: 32673452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Strongyloides stercoralis: a puzzling parasite.
    Luvira V; Watthanakulpanich D; Pittisuttithum P
    Int Health; 2014 Dec; 6(4):273-81. PubMed ID: 25173343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for strongyloidiasis hyperinfection and clinical outcomes.
    Asdamongkol N; Pornsuriyasak P; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2006 Sep; 37(5):875-84. PubMed ID: 17333728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal Strongyloides Hyperinfection Syndrome in an Immunocompromised Patient.
    Pochineni V; Lal D; Hasnayen S; Restrepo E
    Am J Case Rep; 2015 Sep; 16():603-5. PubMed ID: 26348071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for acquiring Strongyloides stercoralis infection among patients attending a tertiary hospital in south India.
    Chordia P; Christopher S; Abraham OC; Muliyil J; Kang G; Ajjampur Ss
    Indian J Med Microbiol; 2011; 29(2):147-51. PubMed ID: 21654109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view.
    Santiago M; Leitão B
    Eur J Intern Med; 2009 Dec; 20(8):744-8. PubMed ID: 19892301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.
    Ashida C; Kinoshita K; Nozaki Y; Funauchi M
    BMC Infect Dis; 2020 Jul; 20(1):470. PubMed ID: 32615937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.